Citius Pharmaceuticals (CTXR) Cash from Financing Activities (2010 - 2026)

Citius Pharmaceuticals (CTXR) has 16 years of Cash from Financing Activities data on file, last reported at -$1.2 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 135.52% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.9 million (up 1946.2% YoY) and the FY2025 annual result came in at $33.3 million, up 233.96% from the prior year.
• Cash from Financing Activities eased to -$1.2 million in Q1 2026, from $20.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $20.9 million in Q4 2025 to a low of -$3.7 million in Q3 2024.
• A 4-year average of $7.0 million and a median of $3.5 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities slumped 545260.12% — and 2025, when it jumped 711.09%.
• Tracing CTXR's Cash from Financing Activities over 4 years: stood at -$687.0 in 2023, then jumped by 374779.91% to $2.6 million in 2024, then jumped by 711.09% to $20.9 million in 2025, then slumped by 105.9% to -$1.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$1.2 million (Q1 2026), $20.9 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.